Neonc Technologies Holdings, INC

NeOnc Technologies Holdings, Inc. announced a scheduled End-of-Phase 1 meeting with the FDA on November 17, 2026, to discuss the development of its CNS cancer therapy, NEO212.

NeOnc Technologies Holdings, Inc. has redeemed all outstanding shares of its Series A Convertible Preferred Stock for cash, simplifying its capital structure and eliminating potential dilution.

NeOnc Technologies Holdings, Inc. reports significant open-market stock purchases by its CEO and Chief Medical Officer following positive Phase 2a results for its NEO100 therapy.

NeOnc Technologies Holdings, Inc. announced the pricing of a registered direct offering of common stock and warrants, raising approximately $15 million.

NeOnc Technologies Holdings, Inc. files an amendment to its Form 8-K to detail Nasim Shomali's appointment to the Audit Committee.

NeOnc Technologies Holdings, Inc. reported the outcomes of its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

NeOnc Technologies Holdings, Inc. has amended its advisory agreement with AFH Holding & Advisory, LLC, establishing a new annual fee structure based on fully diluted market capitalization, while the company continues to grapple with significant operating losses and substantial doubt regarding its ability to continue as a going concern.

NEONC Technologies reported significantly increased net losses in Q3 2025 despite a NASDAQ listing and capital raises, facing substantial doubt about its going concern ability.

NEONC Technologies Holdings, Inc. reported a significantly wider net loss for Q2 2025, driven by increased operating expenses and share-based compensation, while actively pursuing new financing and strategic partnerships.

NeOnc Technologies Holdings reports a substantial net loss for Q1 2025, driven by increased operating expenses, including share-based compensation and advisory fees, despite completing its NASDAQ listing.

NeOnc Technologies Holdings, Inc. files an amendment to its 2025 Form 10-K to include previously omitted Part III information and updated certifications.

Keithly Garnett, CFO of Neonc Technologies Holdings, Inc., reported a transaction in 5,000 shares of common stock on September 15, 2026.

Amir F Heshmatpour, CEO, President, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 50,000 shares of common stock on September 14, 2026.

Thomas C Chen, CEO, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 10,798 shares of common stock on September 11, 2026.

Keithly Garnett, CFO of Neonc Technologies Holdings, Inc., purchased 257 shares of common stock on September 14, 2026 for $3.89 per share.

Amir F Heshmatpour, CEO, President, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 37,000 shares of common stock on September 11, 2026 for $3.67 per share.

Thomas C Chen, CEO, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 12,757 shares of common stock on August 18, 2026 for $5.49 per share.

NeOnc Technologies Holdings, Inc. reports significant losses and a going concern warning, while advancing multiple brain cancer drug candidates and securing recent financing.

NeOnc Technologies Holdings, Inc. reports significant net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidates NEO100 and NEO212 in clinical trials and acquiring new AI and 3D bioprinting platforms.

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company focused on brain cancers, has filed an S-1 registration statement to facilitate the resale of shares tied to a potential $50 million equity line of credit, while disclosing significant financial losses and a 'going concern' warning from its auditors.

NeOnc Technologies is registering the resale of up to 5.7 million shares of its common stock by existing stockholders following its direct listing on the Nasdaq Global Market.

NeOnc Technologies Holdings is set to pursue a direct listing on the Nasdaq Global Market, offering 2,101,313 shares for resale by existing stockholders.

NeOnc Technologies has engaged RBW Capital Partners for financial advisory services related to its direct listing on Nasdaq and a private placement of common stock.

Amir F. Heshmatpour and affiliated entities have disclosed a combined beneficial ownership of 34.3% in NeOnc Technologies Holdings, Inc. following the company's direct listing on the Nasdaq Global Market, including a cashless warrant exercise.

Cinctive Capital Management LP and its affiliates have reported a 9.99% beneficial ownership stake in NeOnc Technologies Holdings, Inc. as of March 31, 2026.